Project Description

Aqualung
Keeping Covid Patients Off Ventilators One Molecule at a Time

Date & Time:

January 15, 12:00 PM ET / 9:00 AM PT
Webinar: Details provided upon RSVP approval

About the Event:

Aqualung CEO, Dr. Skip Garcia has one goal: “Before I hang up my cleats I want to get a solution into the market that can help people survive Acute Respiratory Distress Syndrome.”

Respiratory distress has been in the news lately as it’s a major complication from COVID-19. But even without the pandemic’s additional cases, an average of 500,000 people per year die from it, killing 40-60% of people who contract it.

Dr. Garcia and his team have identified a biomarker which is a key activator of inflammation that causes respiratory distress. Using this discovery, Aqualung has developed ALT-100, an antibody that reduces the inflammation, providing the first treatment for this deadly condition.

Aqualung is well on their way to developing this platform technology having conducted pre-clinical studies with mice, rats, and swine with strong efficacy data. They will prove through rigorous clinical trials they have a novel therapeutic which will not only save lives but reduce overall healthcare costs.

Please join us to hear from Dr. Garcia and learn how Aqualung Therapeutics is on the verge of an important breakthrough in the treatment of Respiratory Disorders.

Share this Event

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.